VERRICA PHARMACEUTICALS INC (VRCA)
US92511W1080 - Common Stock
These stocks are moving in today's after hours session
As the regular session of the US market concludes on Wednesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Verrica Announces Proposed Public Offering
Verrica Announces Proposed Public Offering
WEST CHESTER, Pa., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics...
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.
These stocks are moving in today's session
Which stocks are gapping on Tuesday?
The market is filled with gapping stocks in Tuesday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Get insights into the top gainers and losers of Tuesday's pre-market session.
Top movers in Tuesday's pre-market session
Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition
Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition
– Company reported $0 in product shipments in the third quarter of 2024 and recognized negative net product revenue of $1.9 million, including a provision...
Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference
- Posters to highlight the safety data, tolerability data, and antitumor efficacy data of VP-315 for the treatment of basal cell carcinoma as determined by...
Verrica Pharmaceuticals Announces Restructuring of Commercial Organization
Verrica Pharmaceuticals Announces Restructuring of Commercial Organization
- Company significantly reduces cost structure with a realigned sales, marketing and operational infrastructure - Sales and marketing efforts to focus on...
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York
WEST CHESTER, Pa., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology...
VRCA Stock Earnings: Verrica Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
VRCA stock results show that Verrica Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Why Is Dermatology-Focused Verrica Pharmaceuticals Stock Trading Lower On Wednesday?
On Wednesday, dermatology drug developer Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) released preliminary results from Part 2 of its Phase 2 trial of VP-315 for basal cell carcinoma. The Phase 2 trial is a 2-part, open-label, multicenter, dose-escalation, proof-of-concept study with a safety run-in designed to assess the safety and tolerability, pharmacokinetics, and efficacy of VP-315 when administered intratumorally to adults with biopsy-proven basal cell carcinoma. The study enrolled 92 adult
Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results
Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results
- Reports YCANTH® revenue, net of $4.9M for second quarter of 2024 along with the expansion of YCANTH’s distribution footprint to include Cencora, Inc. as...
Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma
VP-315 was well tolerated with no reported treatment-related serious adverse events All patients treated with VP-315 had a reduction in tumor size with an...
Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024
WEST CHESTER, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics...
Verrica Pharmaceuticals is Now Oversold (VRCA)
Verrica Pharmaceuticals Breaks Below 200-Day Moving Average - Notable for VRCA
7 Short-Squeeze Stocks That Could Beat Down the Bears
Panic can be a cruel emotion, especially when the consequences are uncapped red ink.
Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.
- Dormer Labs has discontinued the sale of all cantharidin-containing products into the United States - YCANTH is the only commercially available, FDA...